Health

Results: 901-912 of 6233

Connext Successfully Completes Dose Escalation Part of CNT201 Phase 1/2 Clinical Trial for Dupuytren's Contracture

Major Study Shows Liver Health Measured with cT1 Predicts Clinical Outcomes

Crown Bioscience Achieves Green Lab Sustainability Certification

ELIQUENT Life Sciences Announces Strategic Acquisition of Azzur Consulting – Strengthening Full-Service Quality & Compliance Capabilities

PR Newswire associated0

Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing

Elegen Expands ENFINIA™ Platform with IVT Ready DNA to Streamline RNA Therapeutics Development

PR Newswire associated0

Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

PR Newswire associated0

Safe Life Acquires AEDMAX.PL, Enters Polish Market

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

George Alzeeb, PhD, Innovation Manager at Brenus Pharma, presenting the company’s latest preclinical data on STC-1010 — an off-the-shelf vaccine-based immunotherapy — during the Late-Breaking session at the American Association for Cancer Research (AACR) Annual Meeting 2025. This poster highlights the potential of STC-1010 to induce a robust anti-tumor response, supporting Brenus Pharma’s novel approach in immuno-oncology and clincial development.

AACR 2025: Brenus Pharma Presents Late-breaking Preclinical Data on its “off-the-shelf” Next-generation Vaccine-based Immunotherapy Candidate, STC-1010, Now Moving to Clinic